Crossject
ISIN
FR0011716265
Ticker
ALCJ
Sector
Sub-Industry
Country
France
Year Founded
2001
ISIN
FR0011716265
Ticker
ALCJ
Sector
Sub-Industry
Country
France
Year Founded
2001
Crossject is revolutionizing the administration of well-established, clinically-proven treatments and bringing unprecedented advantages to patients with its innovative, needle-free auto-injector ZENEO®.
ZENEO® is no less than 12 years of R&D and more than 400 obtained patents.
Currently, 8 treatments are in advanced stages of development, which 7 for emergency situations.
With its unique know-how, Crossject aims to become a world leader in the self-administration of emergency needle free injectables.
100
Worldwide
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 24.06.2024 | None | Other | Buy | EUR 0.00 |
| 14.06.2024 | None | Other | Other | EUR 20,289.19 |
| 06.06.2024 | None | Other | Other | EUR 1,956,324.22 |
| 06.06.2024 | None | Other | Other | EUR 29,763.89 |
| 06.06.2024 | None | Other | Other | EUR 18,988.20 |
| 06.06.2024 | None | Other | Other | EUR 18,616.75 |
| 06.06.2024 | None | Other | Buy | EUR 10,230.53 |
| 06.03.2023 | None | Other | Other | EUR 75,434.70 |
FR0011716265
969500W1VTFNL2D85A65
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.